

PHIL WEISER  
Attorney General

NATALIE HANLON LEH  
Chief Deputy Attorney General

SHANNON STEVENSON  
Solicitor General

TANJA WHEELER  
Associate Chief Deputy Attorney  
General



RALPH L. CARR  
COLORADO JUDICIAL CENTER  
1300 Broadway, 10th Floor  
Denver, Colorado 80203  
Phone (720) 508-6000

## STATE OF COLORADO DEPARTMENT OF LAW

### PUBLIC ADVISORY ON KRATOM PRODUCTS AND REGULATIONS

- Issued August 13, 2025 -

Attorney General Phil Weiser issues this Public Advisory on changes in the law regarding the manufacture and sale of products containing kratom leaf or kratom extract. Due to the increasing availability of consumer products manufactured from the kratom plant, Senate Bill 25-072 was enacted to address kratom. This Public Advisory provides guidance on the updated law and its protections for consumers.

---

#### **Background on Kratom**

Kratom is an extract that comes from the leaves of a Southeast Asian tree and contains chemical compounds (known as “alkaloids”) that can cause side effects when consumed. The most well-studied kratom-related compounds are mitragynine and 7-hydroxymitragynine (“7-OH”). Mitragynine is found in kratom leaves and breaks down into 7-OH when digested.<sup>1</sup> While 7-OH occurs naturally in the kratom plant in smaller amounts (less than 2% of the total alkaloid content), companies have started manufacturing concentrated forms of 7-OH products.

***Consumer Protection Act Violations.*** It is now a specific violation of the Colorado Consumer Protection Act (“CCPA”)<sup>2</sup> to knowingly prepare, distribute, advertise, sell, or offer for sell:

- Adulterated kratom products;<sup>3</sup>
- Kratom products to a minor under the age of 21;<sup>4</sup>
- Kratom products which exceed allowable levels of 7-OH;<sup>5</sup>
- Kratom products that are a confection, mimics a candy product, or appeals to children;<sup>6</sup> or

---

<sup>1</sup> Eastlack SC, Cornett EM, Kaye AD. [Kratom-pharmacology, clinical implications, and outlook: A comprehensive review \(opens new window\)](#). *Pain Ther.* 2020;9(1):55-69. doi:10.1007/s40122-020-00151-x

<sup>2</sup> *Id.* § 6-1-740.

<sup>3</sup> *Id.* § 740(2)(a)(I).

<sup>4</sup> *Id.* § 740(2)(a)(II).

<sup>5</sup> *Id.* § 740(2)(a)(III).

<sup>6</sup> *Id.* § 740(2)(a)(IV).

- Any combustible or vape product containing kratom.<sup>7</sup>

The CCPA also prohibits:

- Display or storage of kratom products in a manner that allows access to minors under the age of 21;<sup>8</sup>
- Kratom products that contain synthetic or semi-synthetic alkaloids;<sup>9</sup> and
- Kratom products that have more than 2% 7-OH of total alkaloids in the kratom product.<sup>10</sup>

Consumers should also be aware that local laws, rules, and regulations related to the manufacture, sale, or distribution of kratom products may vary. Consumers should be familiar with the laws, rules, and regulations of the city or county they reside in, as they may be more restrictive than those contained in Senate Bill 25-072.

***Packaging and Labeling Requirements.*** The law now requires that kratom products sold in Colorado must meet certain labeling and packaging requirements. Each kratom product for sale must have a label containing the following information:

- Identity of any processor who manufactures or distributes the kratom product;<sup>11</sup>
- Full list of ingredients contained in the kratom product;<sup>12</sup>
- Disclosure advising that the product not be used by people under the age of 21, as well as those who are pregnant or breastfeeding;<sup>13</sup>
- Disclosure advising consumers to consult with a health care professional prior to use;<sup>14</sup>
- Disclosure advising that kratom may be habit-forming;<sup>15</sup>
- Disclosure advising that kratom may interact with certain medications;<sup>16</sup>
- The specific disclosure “these statements on the packaging have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.”;<sup>17</sup>
- The specific disclosure “Keep out of reach of children;” and

---

<sup>7</sup> *Id.* § 740(2)(a)(V).

<sup>8</sup> *Id.* § 740(2)(c).

<sup>9</sup> *Id.* § 740(2)(d)(I).

<sup>10</sup> *Id.* § 740(1)(2)(d)(II).

<sup>11</sup> *Id.* § 6-1-740(2)(b)(I)

<sup>12</sup> *Id.* § 740(2)(b)(II)

<sup>13</sup> *Id.* § 740(2)(b)(III)(A)

<sup>14</sup> *Id.* § 740(2)(b)(III)(B)

<sup>15</sup> *Id.* § 740(2)(b)(IV)(A)

<sup>16</sup> *Id.* § 740(2)(b)(IV)(B)

<sup>17</sup> *Id.* § 740(2)(b)(V)

- Directions for use that include:
  - Recommended amount of kratom product per serving;<sup>18</sup>
  - Recommended number of servings per package;<sup>19</sup>
  - Recommended number of servings to safely consume in a 24-hour period;<sup>20</sup> and
  - Amount of mitragynine and 7-OH per serving.<sup>21</sup>

### **Consumer Guidelines for Purchasing Kratom Products**

Consumers should be aware of the following when considering purchasing kratom products from either a physical retail location or a website:

- Understand the risks of consuming certain kratom products, particularly concentrates, such as the potential for addiction, dependence or withdrawal, and consult with your health care provider about any possible interactions with other medications;
- Read the label and know the serving size and servings per container of any kratom product;
- Make sure the identity of the manufacturer or distributor appears on the label of the product;
- Ask for the COA of the product to confirm the ingredients;
- Avoid products that make any type of specific health claim;
- Read consumer reviews and complaints regarding specific kratom products; and
- Be aware of FDA warning letters issued on certain Kratom and/or 7-OH products, such as a recent FDA warning letter issued on July 15, 2025.<sup>22</sup>

If you believe a product violates the CCPA's requirements for kratom products, file a complaint with the Attorney General at [StopFraudColorado.gov](https://stopfraudcolorado.gov). If you suffer any adverse health event, seek immediate medical attention and contact your local health department or poison control center.



PHILIP J. WEISER  
Attorney General

---

<sup>18</sup> *Id.* § 740(2)(b)(VI)(A)

<sup>19</sup> *Id.* § 740(2)(b)(VI)(B)

<sup>20</sup> *Id.* § 740(2)(b)(VI)(C)

<sup>21</sup> *Id.* § 740(2)(b)(VI)(D)

<sup>22</sup> U.S. Food and Drug Administration. [“FDA Issues Warning Letters to Firms Marketing Products Containing 7-Hydroxymitragynine” \(opens new window\)](#). July 15, 2025.